Poster Presentation HUPO 2019 - 18th Human Proteome Organization World Congress

CARP promotes breast cancer metastasis via FOXO3a down-regulation (#495)

Penchatr Diskul-Na-Ayudthaya 1 , Yun-Ui Bae 1 , Ngu Trinh Van 1 , Sumin Seo 1 , Churat Weeraphan 2 , Parunya Chaiyawat 3 , Kittirat Saharat 4 , Daranee Chokchaichamnankit 4 , Chantragan Srisomsap 4 , Jisnuson Svasti 4 , Sujung Song 1 , Jae-won Shim 1 , Seongho Ryu 1
  1. Soonchunhyang Institute of Medi-bio Science (SIMS), Cheonan-si, CHUNGCHEONGNAM-DO,, South Korea
  2. Molecular Biotechnology and Bioinformatics, Prince of Songkla University, Songkla, Thailand
  3. Department of Orthopedics, Laboratory and Research Network Center (OLARN), Chiang Mai University, Chiang Mai, Thailand, Thailand
  4. Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok, Thailand

Triple negative breast cancer (TNBC), a heterogeneous disease of malignancies which are associated with poor prognosis and highly aggressive. Since the treatments of TNBC are still have not establish yet and under investigation and optimization. However, one of the cause of death that reduce patient survival rate is the metastasis of cancer. Aim of this study is to elucidate the mechanism of metastasis in TNBC. we propose that Ankyrin Repeat Domain 1 (ANKRD1) promotes metastasis in breast cancer. ANKRD1 is highly expressed in the malignant metastatic breast cancer cell line compared to that in the non-metastatic breast cancer cells. Likewise, high stage tumors showed higher levels of ANKRD1 compared to those in lower stage of specimens from tissue samples. Both in vitro and in vivo functional studies of ANKRD1 show that ANKRD1 is essential for cell migration and metastasis. Several functional studies have suggested that the AMPK-ACC-FOXO3a pathway plays an important role in tumor metastasis, but there is a lack of knowledge regarding upstream regulators of this axis. We found that ANKRD1 promotes metastasis in breast cancer by suppressing AMPK-ACC-FOXO3a signaling. These findings suggest that ANKRD1 could holds promise in the future for the development of targeted therapies for TNBC and diagnostic strategies for breast cancer metastasis.